Retour

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Health Health

Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024

GlobeNewswire Inc. • 09/05/2024 à 14:30:00
Surrozen, Inc. Common
Address: 171 OYSTER POINT BLVD
Postal Code: 94080
City: SOUTH SAN FRANCISCO
State: CA
Phone Number: 650-475-2820
Website: https://www.surrozen.com
Status: Active
Company Info

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

List Date2021-08-12
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001824893
Composite figiBBG00XY94S95
Share Class figiBBG00XY94SB2
Market Cap30,548,086 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees42
Share Class Shares Outstanding3200000
Weighted Shares Outstanding3198786
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
9.42
9.631
10.205
10.26
10.13
Variance
-5.33%
-5.62%
0.34%
1.28%
0.15%
Open
9.95
10.205
10.17
10.13
10.115
Highest
9.95
10.334
10.466
10.31
10.318
Lowest
9.95
10.325
10.43
10.31
10.215
History
PeriodVarhighestlowest
1 week
-6.87%
10.318
9.95
1 month
-2.92%
9.82
8.74
3 month
-3.56%
13.923
8.74
6 month
34.94%
7.575
5.7
1 year
12.14%
9.4485
4.5
3 year
-93.42%
157.65
4.5
5 year
-93.42%
157.65
4.5
10 year
-93.42%
157.65
4.5
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-08 UNPUB
Assets 74,200,000 63,999,000 53,973,000 UNPUB
Current Assets 67,034,000 57,579,000 48,357,000 UNPUB
Current Liabilities 7,789,000 6,451,000 6,672,000 UNPUB
Equity 63,037,000 55,058,000 45,531,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 63,037,000 55,058,000 45,531,000 UNPUB
Liabilities 11,163,000 8,941,000 8,442,000 UNPUB
Liabilities And Equity 74,200,000 63,999,000 53,973,000 UNPUB
Noncurrent Assets 7,166,000 6,420,000 5,616,000 UNPUB
Noncurrent Liabilities 3,374,000 2,490,000 1,770,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-08 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 3,119,000 8,687,000 -2,500,000 UNPUB
Net Cash Flow, Continuing 3,119,000 8,687,000 -2,500,000 UNPUB
Net Cash Flow From Financing Activities -39,000 187,000 -13,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -39,000 187,000 -13,000 UNPUB
Net Cash Flow From Investing Activities 17,328,000 17,249,000 7,646,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 17,328,000 17,249,000 7,646,000 UNPUB
Net Cash Flow From Operating Activities -14,170,000 -8,749,000 -10,133,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -14,170,000 -8,749,000 -10,133,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-08 UNPUB
Comprehensive Income/Loss -14,106,000 -9,332,000 -10,449,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -14,106,000 -9,332,000 -10,449,000 UNPUB
Other Comprehensive Income/Loss 191,000 55,000 -4,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-08 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -14,297,000 -9,387,000 -10,445,000 UNPUB
Income/Loss From Continuing Operations Before Tax -14,297,000 -9,387,000 -10,445,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -14,297,000 -9,387,000 -10,445,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -14,297,000 -9,387,000 -10,445,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -14,297,000 -9,387,000 -10,445,000 UNPUB
Operating Expenses 14,592,000 10,275,000 11,189,000 UNPUB
Operating Income/Loss -14,592,000 -10,275,000 -11,189,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-11 2022-11-14 2023-03-31
Assets 117,655,000 104,127,000 91,434,000 89,435,000
Current Assets 95,679,000 94,819,000 82,719,000 81,305,000
Current Liabilities 8,115,000 8,524,000 8,654,000 9,732,000
Equity 102,662,000 89,696,000 77,491,000 76,001,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 102,662,000 89,696,000 77,491,000 76,001,000
Liabilities 14,993,000 14,431,000 13,943,000 13,434,000
Liabilities And Equity 117,655,000 104,127,000 91,434,000 89,435,000
Noncurrent Assets 21,976,000 9,308,000 8,715,000 8,130,000
Noncurrent Liabilities 0 0 5,289,000 3,702,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-11 2022-11-14 2023-03-31
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 -16,225,000 8,665,000 -8,401,000
Net Cash Flow, Continuing 0 -16,225,000 8,665,000 -8,401,000
Net Cash Flow From Financing Activities 18,786,000 -18,789,000 -13,000 -2,565,000
Net Cash Flow From Financing Activities, Continuing 18,786,000 -18,789,000 -13,000 -2,565,000
Net Cash Flow From Investing Activities -412,000 13,977,000 22,831,000 38,309,000
Net Cash Flow From Investing Activities, Continuing -412,000 13,977,000 22,831,000 38,309,000
Net Cash Flow From Operating Activities -18,374,000 -11,413,000 -14,153,000 -44,145,000
Net Cash Flow From Operating Activities, Continuing -18,374,000 -11,413,000 -14,153,000 -44,145,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-11 2022-11-14 2023-03-31
Comprehensive Income/Loss -8,257,000 -13,972,000 -13,305,000 -36,126,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,257,000 -13,972,000 -13,305,000 -36,126,000
Other Comprehensive Income/Loss -310,000 -47,000 52,000 -122,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-11 2022-11-14 2023-03-31
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses UNPUB UNPUB UNPUB 48,504,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB 48,504,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,947,000 -13,925,000 -13,357,000 -36,004,000
Income/Loss From Continuing Operations Before Tax -7,947,000 -13,925,000 -13,357,000 -36,004,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,947,000 -13,925,000 -13,357,000 -36,004,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,947,000 -13,925,000 -13,357,000 -36,004,000
Net Income/Loss Available To Common Stockholders, Basic -7,947,000 -13,925,000 -13,357,000 -36,004,000
Operating Expenses 14,493,000 14,072,000 13,605,000 56,839,000
Operating Income/Loss -14,493,000 -14,072,000 -13,605,000 -44,339,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 12,500,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-15 2022-03-28
Assets UNPUB UNPUB 150,636,000 137,174,000
Current Assets UNPUB UNPUB 114,002,000 105,189,000
Current Liabilities UNPUB UNPUB 12,541,000 13,573,000
Equity UNPUB UNPUB 123,731,000 109,700,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 123,731,000 109,700,000
Liabilities UNPUB UNPUB 26,905,000 27,474,000
Liabilities And Equity UNPUB UNPUB 150,636,000 137,174,000
Noncurrent Assets UNPUB UNPUB 36,634,000 31,985,000
Noncurrent Liabilities UNPUB UNPUB 14,364,000 13,901,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-15 2022-03-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 26,710,514 -1,891,000
Net Cash Flow, Continuing UNPUB UNPUB 26,710,514 -1,891,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 124,630,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 124,630,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -77,708,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -77,708,000
Net Cash Flow From Operating Activities UNPUB UNPUB -36,673,486 -48,813,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -36,673,486 -48,813,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-15 2022-03-28
Comprehensive Income/Loss UNPUB UNPUB -14,035,000 -54,767,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -14,035,000 -54,767,000
Other Comprehensive Income/Loss UNPUB UNPUB -16,000 -119,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-15 2022-03-28
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 14,033,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 14,033,000 UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -14,019,000 -54,648,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -14,019,000 -54,648,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -14,019,000 -54,648,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -14,019,000 -54,648,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -14,019,000 -54,648,000
Operating Expenses UNPUB UNPUB 13,705,000 54,391,000
Operating Income/Loss UNPUB UNPUB -13,705,000 -54,391,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 14,000 0
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
★★
15:30
United States
News Stream
Health Health
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
GlobeNewswire Inc. • 1w ago
News Clinical Study
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
GlobeNewswire Inc. • 1mo ago
Health Health
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
GlobeNewswire Inc. • 1mo ago
Stocks Major shareholder announcements
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
Surrozen Provides Corporate Update on Clinical Programs
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis
GlobeNewswire Inc. • 4mo ago
Health Health
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today they co-authored a publication with Stanford Medicine and Columbia University scientists in Nature Communications. The results observed with systemic administration of Surrozen’s Frizzled-4 (Fzd4) selective Wnt mimetic antibody in a disease model of ischemic stroke reveal the potential for this novel mechanism of action to reverse blood-brain-barrier (BBB) dysfunctions such as leakage in the surrounding brain tissue, death of surrounding tissue, and tissue swelling while improving neurologic function.
GlobeNewswire Inc. • 11mo ago
News Health
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today they co-authored a publication with Stanford Medicine and Columbia University scientists in Nature Communications. The results observed with systemic administration of Surrozen’s Frizzled-4 (Fzd4) selective Wnt mimetic antibody in a disease model of ischemic stroke reveal the potential for this novel mechanism of action to reverse blood-brain-barrier (BBB) dysfunctions such as leakage in the surrounding brain tissue, death of surrounding tissue, and tissue swelling while improving neurologic function.
GlobeNewswire Inc. • 11mo ago
Stocks Earnings Releases and Operating Results
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023
GlobeNewswire Inc. • 1y ago
Stocks Earnings Releases and Operating Results
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023
GlobeNewswire Inc. • 1y ago
News News
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks Investment Research • 1y ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT